10-Q: Akoya Biosciences Reports Q3 2024 Results: Revenue Declines Amid Restructuring Efforts

Akoya Biosciences' Q3 2024 results show a decrease in revenue and a net loss, alongside restructuring and cost-saving initiatives.

Summary

• Akoya Biosciences reported a net loss of $10.5 million for the third quarter of 2024, compared to a $12.9 million loss in the same period of 2023.
• Total revenue for Q3 2024 was $18.8 million, a decrease from $25.2 million in Q3 2023, primarily due to lower instrument sales.
• Product revenue decreased by 32% year-over-year, while service and other revenue decreased by 9%.
• The company's gross profit was $11.7 million, down from $15.3 million in the prior year, with a gross margin of 62%.
• Operating expenses were reduced to $20.1 million, compared to $26.8 million in the same quarter last year, due to cost-cutting measures.
• The company recorded a $1.7 million restructuring charge related to workforce reductions.
• Akoya's cash, cash equivalents, and marketable securities totaled $39.3 million as of September 30, 2024.
• The company has an accumulated deficit of $277.2 million and has used $41.1 million in cash from operations during the first nine months of 2024.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive cost-cutting measures but significant concerns about revenue decline, profitability, and the company's ability to continue as a going concern. The overall sentiment is negative due to the financial challenges and uncertainty.

Positives

• The company's net loss improved to $10.5 million in Q3 2024 from $12.9 million in Q3 2023.
• Operating expenses decreased by 25% year-over-year, indicating successful cost-cutting measures.
• Gross margin increased slightly to 62% due to a higher mix of consumables.
• Consumable revenue increased due to a larger installed base.
• The company is actively working to improve results of operations in an effort to achieve cash flow positivity.

Negatives

• Total revenue decreased by 25% year-over-year, primarily due to a significant drop in instrument sales.
• Product revenue decreased by 32% year-over-year.
• The company's gross profit decreased by 23% year-over-year.
• The company recorded a $1.7 million restructuring charge related to workforce reductions.
• The company has an accumulated deficit of $277.2 million.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• The company is subject to financial covenants under its debt agreement, and there is uncertainty about maintaining compliance.
• The company may need to seek additional equity or debt financing, which may not be available on acceptable terms.
• The company's future success depends on its ability to commercialize products and achieve profitability.
• The company's revenue is heavily reliant on instrument sales, which can fluctuate significantly.
• The company faces risks related to competition, protection of proprietary technology, and market acceptance of its products.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future but plans to improve results of operations in an effort to achieve cash flow positivity. The company also intends to seek a waiver, refinance the outstanding borrowings or otherwise mitigate concerns with Midcap Financial Trust or another lender.

Management Comments

• Management is focused on increasing sales of PhenoCycler and PhenoImager platforms.
• Management believes the market is still evolving and relatively underpenetrated.
• Management expects recurring revenue to increase as the installed base expands.
• Management aims to mitigate downward pressure on average selling prices by increasing the value proposition of their products.
• Management plans to continue to invest in research and development to enhance existing products and develop new products.

Industry Context

The spatial biology market is rapidly evolving, and Akoya is positioned as a key player with its PhenoCycler and PhenoImager platforms. The company's focus on end-to-end solutions and clinical applications aligns with industry trends, but it faces competition and the need to demonstrate market adoption and profitability.

Comparison to Industry Standards

• Akoya's revenue decline contrasts with the growth seen in some other life science tools companies, such as Bio-Rad Laboratories and Illumina, although these companies operate in different segments.
• The company's gross margin of 62% is within the range of other life science companies, but its operating losses are a concern compared to more established players.
• Akoya's instrument placement numbers are lower than some competitors, indicating a need to accelerate sales and market penetration.
• The company's reliance on debt financing and the uncertainty around its going concern status are significant risks compared to companies with stronger balance sheets.

Related Party Transactions

• The company incurred costs of goods sold of approximately $438 and $1,762, respectively, related to sales of consumables manufactured by and shipped from Argonaut Manufacturing Services Inc. (AMS) during the three months ended September 30, 2024 and 2023.
• The company incurred research and development expenses of approximately $188 and $101, respectively, with a software-as-a-service provider, who provides software development services to the Company, during the three months ended September 30, 2024 and 2023.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and uncertainty about its ability to continue as a going concern.
• Employees have been impacted by workforce reductions and may face further uncertainty.
• Customers may be concerned about the company's long-term viability and its ability to support its products.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• The company intends to seek a waiver, refinance the outstanding borrowings or otherwise mitigate concerns with Midcap Financial Trust or another lender.
• The company plans to continue to grow its business while improving results of operations in an effort to achieve cash flow positivity.
• The company will continue to focus on increasing sales of its PhenoCycler and PhenoImager platforms.
• The company will continue to invest in research and development to enhance existing products and develop new products.

Key Dates

Keywords

spatial biology, phenotyping, instruments, reagents, revenue, net loss, restructuring, cost reduction, financial covenants, going concern